Bright Minds Biosciences Inc.
DRUG
Kedudukan dalam Saham
#12821
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Harga Saham
$52.77
Modal Pasaran
$520.53M
Perubahan (1 hari)
2.87%
Perubahan (1 tahun)
-23.32%
Negara
US
Perdagangan Bright Minds Biosciences Inc. (DRUG)
Kategori
Healthcare
Modal pasaran bagi Bright Minds Biosciences Inc.(DRUG)
Modal Pasaran: $520.53M
Sehingga October 2026, Bright Minds Biosciences Inc. mempunyai modal pasaran sebanyak $520.53M. Ini menjadikan Bright Minds Biosciences Inc. syarikat ke-12821st paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Bright Minds Biosciences Inc. dari 2021 hingga 2026
DRUG berbanding dengan 5 teratas yang paling popular stocks
